NCT00116935View on ClinicalTrials.gov

Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)

PHASE3CompletedINTERVENTIONAL

Enrollment

400

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Sarcoma

Interventions

DRUG

imatinib mesylate

imatinib 400 mg/day orally qd for 12 months

DRUG

imatinib

imatinib 400 mg/d orally qd for 36 months

DRUG

imatinib

imatinib 400 mg/d orally qd for 36 months

Trial Locations (1)

SE-221 85

Scandinavian Sarcoma Group, Southern Swedish Regional Tumour Registry, Lund University Hospital, Lund

All Listed Sponsors

lead

Scandinavian Sarcoma Group

OTHER

NCT00116935 - Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) | Biotech Hunter | Biotech Hunter